BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.